Skip to main
SIBN

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE is poised for increased revenue growth with the launch of their new INTRA Ti implant and the potential for new products targeting clinical adjacencies. The company also expects to generate positive EBITDA in 2026 and increase international market penetration, further driving revenue and profitability. Additionally, the recent strategic distribution partnership with Smith Nephew for trauma and spine products shows potential for deeper penetration into larger Tier 1 and 2 accounts, creating room for growth and solidifying SI-BONE's position as a leader in the minimally invasive sacroiliac joint fusion market.

Bears say

SI-BONE is facing competition in the market, their iFuse patents are set to expire, and their sales force and profitability may not execute as expected. Additionally, they are facing potential market dynamics and slower progress ramping profitability. Their upcoming product launches may serve as catalysts, but there are still risks to consider, such as competitive launches and potential challenges with ramping revenue and profitability. With a slower growth outlook compared to peers and potential challenges ahead, the analyst has a negative outlook on SI-BONE's stock.

SI-BONE Inc (SIBN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, SI-BONE Inc (SIBN) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.